Cite
Tsuda E, Fukuda C, Okada A, et al. Characterization, pharmacokinetics, and pharmacodynamics of anti-Siglec-15 antibody and its potency for treating osteoporosis and as follow-up treatment after parathyroid hormone use. Bone. 2021;155:116241doi: 10.1016/j.bone.2021.116241.
Tsuda, E., Fukuda, C., Okada, A., Karibe, T., Hiruma, Y., Takagi, N., Isumi, Y., Yamamoto, T., Hasegawa, T., Uehara, S., Koide, M., Udagawa, N., Amizuka, N., & Kumakura, S. (2021). Characterization, pharmacokinetics, and pharmacodynamics of anti-Siglec-15 antibody and its potency for treating osteoporosis and as follow-up treatment after parathyroid hormone use. Bone, 155116241. https://doi.org/10.1016/j.bone.2021.116241
Tsuda, Eisuke, et al. "Characterization, pharmacokinetics, and pharmacodynamics of anti-Siglec-15 antibody and its potency for treating osteoporosis and as follow-up treatment after parathyroid hormone use." Bone vol. 155 (2021): 116241. doi: https://doi.org/10.1016/j.bone.2021.116241
Tsuda E, Fukuda C, Okada A, Karibe T, Hiruma Y, Takagi N, Isumi Y, Yamamoto T, Hasegawa T, Uehara S, Koide M, Udagawa N, Amizuka N, Kumakura S. Characterization, pharmacokinetics, and pharmacodynamics of anti-Siglec-15 antibody and its potency for treating osteoporosis and as follow-up treatment after parathyroid hormone use. Bone. 2021 Oct 27;155:116241. doi: 10.1016/j.bone.2021.116241. Epub 2021 Oct 27. PMID: 34715394.
Copy
Download .nbib